PDCD1 and non-small cell lung carcinoma: A phase 1b trial assessed sintilimab (a PD-1 inhibitor) combined with anlotinib (a multi-target tyrosine kinase inhibitor with anti-angiogenic action) in the frontline setting for advanced NSCLC (84).